The IMPACT-AD team's Alzheimer's disease testing innovation for amyloid-beta proteoforms has been published in a leading scientific journal!
The first method to identify both sporadic and autosomal dominant Alzheimer's disease
This is the first method to identify both sporadic AD (by wt-Aβ42 and wt-Aβ40 concentration) and autosomal dominant AD (by identification of pathogenic APP variants) in one anatysis, enabling biomarker testing without a priori knowledge of the genetic makeup of an individual.
Fully-automated & calibrated to the international standard
Development of an automated workflow and selection of appropriate instrumentation enabled deployment of this method for routine patient testing in Canada!